Ed Shovelin on CRP-A Utilization in Diverse Research Areas
Ed Shovelin, Operations and Engineering Manager at Pplus Medical Limited, reposted from Pplus Medical Limited on LinkedIn:
”Its great to see the different research areas that scientists are utilizing CRP-A in.”
Quoting Pplus Medical Limited‘s post:
”CRP-A by Pplus Medical Limited is increasingly becoming a trusted platelet activator for leading researchers around the world, and we’re delighted to highlight the innovative work it helps make possible.
This week we want to share the following work by Professor Gawaz and his team at the Hospital of the university of Tübingen: Effect of phosphodiesterase inhibitors on platelet function.
Hypothesis: PDE2, PDE3 and PDE5 display differential effects on platelet-mediated thrombosis.
Methods: Compare the effects of PDE inhibition by Ibudilast, a non-selective inhibitor of several PDEs with preference towards PDE3, PDE4, PDE10 and PDE11, IBMX, a nonspecific PDE inhibitor and Sildenafil, a potent selective PDE5 inhibitor, respectively, on platelet activation, aggregation and thrombus formation.
How CRP-A was used: CRP-A was used to induce GPVI-mediated platelet activation, aggregation and thrombus formation.
Key Findings: Platelet activation by ADP via P2Y12 and TRAP6 via PAR1 showed a greater response to PDE inhibitors than platelet activation by CRP-A via GPVI”
Read the full article here.
Article: Effect of phosphodiesterase inhibitors on platelet function
Authors: Ravi Hochuli, Valerie Dicenta, Zoi Laspa, Manuel Sigle, Tobias Harm, Tatsiana Castor, Anne-Katrin Rohlfing, Meinrad Paul Gawaz

Stay updated on all scientific advances with Hemostasis Today.
-
Aug 14, 2026, 08:17Maha Othman: Celebrating Research and Collaboration at the Sinclair Cancer Research Institute 2026 Annual Retreat
-
Aug 14, 2026, 06:26Delivering Gene Therapy in Hemophilia – ISTH
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation